Etomidate

CLINICAL USE

Induction of anaesthesia

DOSE IN NORMAL RENAL FUNCTION

150–300 mcg/kg

PHARMACOKINETICS

  • Molecular weight                           :244.3
  • %Protein binding                           :76
  • %Excreted unchanged in urine     : 2
  • Volume of distribution (L/kg)       :2–4.5
  • half-life – normal/ESRD (hrs)      :4–5/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unknown dialysability. Dose as in normal renal function
  • HD                     :Unknown dialysability. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAdrenergic neurone blockers: enhanced hypotensive effectAntihypertensives: enhanced hypotensive effect

  • Antidepressants: avoid MAOIs for 2 weeks before surgery; increased risk of arrhythmias and hypotension with tricyclics
  • Antipsychotics: enhanced hypotensive effect

    ADMINISTRATION

    Reconstition

    Route

    Intravenous injection only

    Rate of Administration

    Comments

    OTHER INFORMATION

    In cases of adrenocortical gland dysfunction and during very long surgical procedures, a prophylactic cortisol supplement may be required (e.g. 50–100 mg hydrocortisone)

  • Related News